Diagnosis of intestinal metaplasia in gastric mucosa using Linked Color Imaging(LCI)
Not Applicable
Recruiting
- Conditions
- Stomach tumor-related lesion
- Registration Number
- JPRN-UMIN000019438
- Lead Sponsor
- Jichi Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Acute abdomen 2) Severe inflammation 3)Poor general condition patients who has risk for performing endoscopy such as ileus, perforation of intestine, pancreatitis respiratory disorder, heart failure, acquired hemophilia, intestinal stricture and large ulcer or tumor of digestve tract. 3) Patients who take peroral multiple drugs including anti-platelets and anti-coagulants, leading to difficulty to take a biopsy. 5) Patients who experienced entry of this study. 6) Patient who is judged to be unsuitable for this clinical trial. 7) Patients who are difficult to be sublect the informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastric biopsied specimens will be taken from the purple change mucosa suspicious of intestinal metaplasia by LCI images, compared with BLI images. Similarly, specimens will be taken from brown change mucosa suspicious of non-intestinal metaplasia. Based on the pathological findigs, sensitivity, specificity and accuracy will be evaluated.
- Secondary Outcome Measures
Name Time Method Based on histological assessment of endoscopically resected specimens, the usefulness of LCI will be evaluated about the extent of tumor by color contrast between the tumor and the surrounding mucosa. .In addition, the color difference will be measuerd using a color space International Lighting Commission recommended in 1976 in order to quantify such color contast and assess visibility of tumors by LCI.